ONC is the ticker symbol for BeOne Medicines Ltd., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ONC with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ONC a good stock to buy?

13F Pro's AI ranking engine scores ONC at 74.9/100, ranked #104 of 2,962 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for ONC is available at https://13fpro.ai/company/ONC. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source ONC data?

All BeOne Medicines Ltd. fundamentals and ownership data come directly from SEC EDGAR. BeOne Medicines Ltd. files with the SEC under CIK 1651308. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

BeOne Medicines Ltd.(ONC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BeOne Medicines Ltd. (ONC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ONC at 74.9/100 on a 32-signal composite quality model, placing it at rank #104 of 2,962 stocks — the top 5% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BeOne Medicines Ltd. reports quarterly revenue of $1.7B, net income of $237.0M, free cash flow of $435.3M. Top institutional holders of ONC by reported 13-F value include BAKER BROS. ADVISORS, PRIMECAP MANAGEMENT, Capital International Investors, based on the most recent SEC filings. ONC trades on the Nasdaq exchange and files with the SEC under CIK 1651308. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ONC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BeOne Medicines Ltd. directly from SEC EDGAR.

AI Quality Score

74.9/100

AI Rank

#104

Revenue

$1.7B

Net Income

$237.0M

Free Cash Flow

$435.3M

ONC key financials by period

BeOne Medicines Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$5.3B	$286.9M	8.4%
FY 2024	10-K	$3.8B	$-644.8M	-14.9%
FY 2023	10-K	$2.5B	$-881.7M	-49.1%
FY 2022	10-K	$1.4B	$-2.0B	-126.4%
FY 2021	10-K	$1.2B	$-1.5B	-122.3%
FY 2020	10-K	$308.9M	$-1.6B	—

Institutions holding ONC

Institutional investors reporting a position in BeOne Medicines Ltd. on SEC Form 13F.
Institution	Shares	Value	Reported
BAKER BROS. ADVISORS	8,801,567	$2.5B	2026-06-30
PRIMECAP MANAGEMENT	5,007,931	$1.4B	2026-06-30
Capital International Investors	4,210,221	$1.2B	2026-06-30
FMR	2,478,527	$706.3M	2026-06-30
Capital World Investors	2,249,582	$641.1M	2026-06-30
CITADEL ADVISORS	1,425,517	$406.2M	2026-06-30
Temasek (Private) Ltd	845,729	$241.0M	2026-06-30
PRICE T ROWE ASSOCIATES	758,752	$216.2M	2026-06-30
BlackRock	694,618	$197.9M	2026-06-30
MILLENNIUM MANAGEMENT	543,323	$154.8M	2026-06-30

SEC EDGAR: CIK 1651308 →

BeOne Medicines Ltd.

ONC

NasdaqMega CapHealthcare

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

74.9/100

Rank #104 of 2,962 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving ONC's Business? Latest 10-Q Breakdown

27/27 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue surged 30% to $1.7B driven by BRUKINSA growth of 31%, achieving diluted EPS of $0.16 GAAP and $2.05 per ADS.

Biggest Revenue Drivers

BRUKINSA (zanubrutinib)$1,247.6M+31.4% YoY

Robust demand growth and strong market share gains in U.S., Europe, and Rest of World

TEVIMBRA (tislelizumab)$228.5M+18.1% YoY

Growth from anti-PD-1 antibody commercialization across major markets

Biggest Revenue Drivers

Total revenue: $1,705.1M+29.6% YoY

BRUKINSA (zanubrutinib)$1,247.6M+31.4% YoY

Robust demand growth and strong market share gains in U.S., Europe, and Rest of World

TEVIMBRA (tislelizumab)$228.5M+18.1% YoY

Growth from anti-PD-1 antibody commercialization across major markets

Amgen licensed products (XGEVA, BLINCYTO, KYPROLIS)$157.3M+24.5% YoY

Increased XGEVA sales volume in China under Amgen collaboration

Other revenue$25.3M+91.1% YoY

Royalty revenue from Amgen IMDELLTRA sales and Novartis broad markets agreement

Largest Expense Items

Research and development$612.3M+16.6% YoY

Increased investment in pipeline advancement including BTK CDAC, CDK4, and PRMT5 programs plus higher Amgen co-development costs

Selling, general and administrative$593.2M+10.3% YoY

Continued investment in global commercial expansion primarily in U.S. and Europe

Cost of sales - product$174.5M+6.0% YoY

Production productivity improvements and favorable product mix

Margins: Gross margin expanded to 89.6% for Q2 2026 from 87.4% YoY, driven by higher BRUKINSA proportion of sales mix and manufacturing efficiency gains. Operating margin improved significantly as revenue growth outpaced expense growth, with operating expenses growing only 13.4% while revenue grew 29.6%.

Watch Items from the Filing

Amgen royalty sale liability of $906.3M recorded; repayment depends on future IMDELLTRA royalties through at least 2041 with effective imputed interest rate of 11.0%.
Total debt obligations of $1,073.1M outstanding; $201.1M due within 12 months. Facilities Agreement requires compliance with financial covenants including minimum cash interest coverage ratio of 5.00x and maximum net leverage ratio of 2.50x.
BRUKINSA faces potential generic competition; Zydus filed ANDA in February 2026 with Paragraph IV certifications challenging patents. Company initiated patent infringement litigation but generic composition-of-matter patent remains intact until 2034.
AbbVie litigation alleging misappropriation of trade secrets for BTK degrader program BGB-16673 remains ongoing; motion to dismiss denied May 2026; no trial date scheduled.
Operating cash flow of $664.2M for first six months 2026 versus $307.7M YoY, representing positive operating cash generation trajectory and reduced reliance on external financing.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →